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Abstract
In phase I cancer clinical trials, the maximum tolerated dose of a new drug is often found by
a dose-escalation method known as the A + B design. We have developed an interactive
web application, AplusB, which computes and returns exact operating characteristics of
A + B trial designs. The application has a graphical user interface (GUI), requires no pro-
gramming knowledge and is free to access and use on any device that can open an internet
browser. A customised report is available for download for each design that contains tabu-
lated operating characteristics and informative plots, which can then be compared with
other dose-escalation methods. We present a step-by-step guide on how to use this appli-
cation and provide several illustrative examples of its capabilities.
Introduction
In oncology, phase I trials are the first experimentation of a new drug in humans. They are pri-
marily concerned with assessing how safe a drug is and aim to identify the drug’s Maximum
Tolerated Dose (MTD). Definitions of the MTD vary; the National Cancer Institute (NCI)
defines the MTD as “the highest dose of a drug or treatment that does not cause unacceptable
side effects” [1], whereas in statistical literature the MTD is defined as “the dose expected to
produce some degree of medically unacceptable, dose-limiting toxicity (DLT) in a specified
proportion of patients (e.g. 30%)” [2]. What is classed as a DLT will depend on the trial being
conducted, but it is often defined as at least one grade 3 or higher toxicity as per the NCI Com-
mon Terminology Criteria for Adverse Events (CTCAE) [3]. Phase I oncology trials are usually
dose-escalation studies, where the dosage given to a cohort of patients increases if the previous
cohort tolerated their treatment; this continues either until the number of DLTs experienced in
the current cohort inhibit further escalation, or the maximum sample size is reached. Rule-
based designs, where fixed rules applied to counts of DLT/non-DLT responses govern the esca-
lation and de-escalation of doses, have long been popular with clinicians in phase I trials of
cytotoxic treatments [4, 5]. The appeal of rule-based designs is that they do not require the
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dose-toxicity relationship to be modelled according to some function of dose, and that dose
escalation decisions are entirely prescriptive.
One family of rule-based designs used for phase I trials is A + B designs [6], which includes
the commonly used 3 + 3 design [4, 7]. In general, small cohorts of patients receive a dosage of
a new treatment and the number of patients in the cohort that experience a DLT determines
whether the next cohort receive a higher, equal, or lower dosage than the current cohort. Sev-
eral papers [6, 8–10] have documented analytical studies of general A + B designs and offered
different operating characteristics relevant to phase I clinical trials. Lin and Shih [6] derived
several statistical formulae for the operating characteristics of A + B designs, both with and
without dose de-escalation. These formulae are implemented in the S-Plus program pmtd
(code available from author upon request), which calculated the expected sample size, the aver-
age number of DLTs per dose level, the probability of recommending each dose as the MTD
and an approximation of the probability of assigning patients to each dose; however, they did
not derive the exact distribution for the trial sample size, or the distribution of the percentage
of trial patients experiencing a DLT. Reiner et al. [8] wrote a PASCAL program for the 3 + 3
design to calculate the probability of recommending a dose as the MTD conditional on the trial
stopping after different numbers of participants, the experimentation percentages at each dose
and also the expected number of patients in a trial. Kang and Ahn [9] used a FORTRAN 77
program to determine the exact distribution of the MTD for the 3 + 3 design over a set of pre-
determined doses, given probabilities of DLT at each dose level. However, information regard-
ing the dose allocation and DLT outcomes of each cohort that would allow exact distributions/
probabilities for other relevant quantities to be calculated was discarded. Much of the past
work in exploring the operating characteristics of the 3 + 3 design has either been lost since
publication, or presented a limited set of operating characteristics.
Whilst we do not necessarily advocate using A + B designs for dose-escalation studies, it is
important that their operating characteristics can be clearly, easily and quickly summarised
because of their ubiquity in clinical practice. The objective of this paper is to provide a tool that
comprehensively summarises A + B designs so that they may be compared with other dose-esca-
lation methods and aid the trial design process. The underlying programs in our web-based
application, AplusB, determine all possible trials for a particular A + B design (with or without
dose de-escalation) and are based on those from the threep3 program (available in the R pack-
age bcrm [11]), which only offers operating characteristics for the 3 + 3 design with dose de-
escalation [12]. We describe the AplusB application and how it is used in the Methods section. In
the Results section we investigate the operating characteristics of different designs applied to four
example dose-toxicity scenarios and show the outputs that the user is provided with. We con-
clude with a summary of the AplusB application and its potential use in clinical practice.
Methods
The AplusB application is written in the R programming language [13] and made freely avail-
able using the Shiny package [14]. To access the application online, visit http://www.mrc-bsu.
cam.ac.uk/software and view theWeb applications subsection. The R code for AplusB can be
downloaded from GitHub at https://github.com/graham-wheeler/AplusB.
The A + B design
The A + B design is a rule-based approach for conducting dose-escalation studies; the 3 + 3
design [4, 7] is one specific sub-design that is implemented in the vast majority of phase I can-
cer clinical trials [5, 15–17]. The A + B design obtains its name from A and B, two positive inte-
gers that represent the number of potential patients at a given dose level. The full specification
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of the design requires six parameters; integers A, B, C, D and E, and an indicator of whether
dose de-escalation is permitted or not. Specifically, parameters A − E are defined as follows: A
is the number of patients in the first cohort that are assigned to a dose; B is the number of
patients in the second cohort (if required) that are assigned to a dose; C is the minimum num-
ber of DLTs needed out of A patients to assign Bmore; D is the maximum number of DLTs
needed out of A patients to assign Bmore, otherwise the trial stops/de-escalates; E is the maxi-
mum number of DLTs out of A + B patients allowed so that the dose may be escalated for the
next cohort of A patients. The decision trees that the A + B design follows, both without and
with dose de-escalation, are best shown as flow charts (Fig 1; Fig 2). In general, if the number
of patients experiencing a DLT at a particular dose level is below a lower bound, then the dose
is increased for the next cohort; if it is above an upper bound, the trial is stopped or dose de-
Fig 1. Design schematic of the A + B design without dose de-escalation.
doi:10.1371/journal.pone.0159026.g001
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escalated, and if it lies between these bounds, the next cohort of patients receive the same dose
level. The constants {A, B, C, D, E} can be replaced with {3, 3, 1, 1, 1}, with dose de-escalation
not permitted, to obtain the traditional 3 + 3 design [4, 7].
Using the application
The application has a simple graphical user interface (GUI), where the user specifies Scenario
parameters and Design parameters to control the set-up of the trial (Fig 3). The scenario
Fig 2. Design schematic of the A + B design with dose de-escalation.
doi:10.1371/journal.pone.0159026.g002
AplusB: AWeb Application for Phase I Trials
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Fig 3. Graphical user interface (GUI) for scenario and design parameters.
doi:10.1371/journal.pone.0159026.g003
AplusB: AWeb Application for Phase I Trials
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parameters to be specified are the number of dose levels and the true probabilities of DLT for
each dose. Changing the number of dose levels will automatically change the number of sliders
available to specify true DLT probabilities. The design parameters to be specified are: the inte-
gers {A, B, C, D, E}, which determine the rules for escalation, de-escalation (if permitted) and
trial termination; the choice of dose de-escalation (via a checkbox); and the confidence level for
confidence intervals for the estimated DLT probability at the selected MTD. After these have
been specified, clicking the Get design properties button will begin the computations and dis-
play the results in the three available output tabs: Scenario plots; Scenario operating character-
istics; and Design operating characteristics (Fig 4).
The Scenario plots tab shows four bar charts: the sample size distribution (top left); experi-
mentation percentages at each dose level (top right); MTD recommendation percentages at each
dose level (bottom left); and the distribution of DLT rates (bottom right). The Scenario operating
characteristics tab provides a summary of the sample size distribution, experimentation and
MTD recommendation percentages for each dose level, and for different intervals of true DLT
probability (specifically [0, 0.2], (0.2, 0.4], (0.4, 0.6], (0.6, 0.8], and (0.8, 1]). This tab also provides
the Expected Toxicity Level (ETL), the mean number of DLTs and the Expected Overall Toxicity
Rate (EOTR), all of which we define in the Operating characteristics subsection. The Design
Fig 4. Output tabs for AplusB application. The Scenario plots tab shows the performance of four operating characteristics. The Scenario
operating characteristics tab provides tabular and numerical summaries of key operating characteristics that depend on the DLT
probabilities chosen on the left-hand panel. The Design operating characteristics tab shows operating characteristics dependent only upon
the design selected, specifically confidence intervals and the tipping point.
doi:10.1371/journal.pone.0159026.g004
AplusB: AWeb Application for Phase I Trials
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operating characteristics tab provides two types of confidence interval for empirical data collec-
tions that are to be found at the MTD identified in a trial; for example, in a 3 + 3 trial without
dose de-escalation, the trial will end with either no DLTs out of three patients at the MTD, or
one DLT out of six patients. Also provided is a new operating characteristic called the tipping
point of the design, which we define in the following subsection and discuss further in S1 Text.
Operating characteristics
Given an A + B design specified by {A, B, C, D, E}, the dose de-escalation indicator and J dose
levels denoted by dj (j = {1, . . ., J}), we can calculate several operating characteristics of interest.
The operating characteristics provided by AplusB consider each possible trial pathway, defined
as the sequence of dose levels each cohort receives, along with the number of patients and num-
ber of DLTs per cohort, and the probability of each trial pathway occurring (Fig 5). Each trial
pathway is unique, and some trial pathways are more likely to occur than others (e.g. a scenario
of five dose levels with a large true probability of DLT at dose level 1 is more likely to lead to
experimentation at dose level 1 only rather than escalate all the way to dose level 5). Therefore,
the chance of every possible trial pathway occurring, no matter how remote, should be cor-
rectly incorporated into operating characteristic calculations. For a particular A + B design and
dose-toxicity scenario, the distribution of trial pathways is used by AplusB to accurately com-
pute operating characteristics; in the “Comparison to pmtd program” subsection, we explore
how the calculations of experimentation percentages in AplusB differ to those in another pro-
gram, pmtd. For an A + B design with true DLT probabilities specified, AplusB computes the
sample size distribution, MTD recommendation probabilities and experimentation probabili-
ties per dose level, the ETL (the expected probability of DLT at the MTD) and EOTR (the
expected proportion of patients experiencing DLTs), and the distribution of DLT rates. Fur-
thermore, regardless of the true DLT probabilities specified, AplusB also provides confidence
intervals (the level of confidence can be chosen by the user) for the estimated probability of
DLT given possible empirical data obtained at the dose chosen as the MTD at the end of the
trial, and a new design operating characteristic called the tipping point. We provide formulae
for these operating characteristics in S1 Text.
The tipping point is the true DLT probability a dose must have at which the chance of escalat-
ing to the next dose level is equal to the chance of not escalating (i.e. de-escalating or stopping
the trial). For an A + B design with de-escalation permitted, we can say that the probability of
choosing a dose with true probability of DLT above the tipping point will be at most 50%, i.e. we
are more likely to select one of the doses with true probability of DLT below the tipping point.
However, for an A + B design with de-escalation not permitted, we can say that the modal MTD
(that is, the dose most likely to be chosen as the MTD) will have a probability of DLT less than
or equal to the tipping point (see S2 Text for proof). This implies that for the classical 3 + 3
design with {C, D, E} = {1, 1, 1} and dose de-escalation not permitted, which has a tipping point
of 0.297, the dose most likely to be chosen as the MTD will in fact have a true probability of
DLT less than or equal to 29.7%, and not 33% that is often assumed [18].
Downloadable report
Once design properties have been calculated and presented in the browser window, the user
may click on the Download report (PDF) button in the bottom-left of the screen. This produces
a two-page PDF report with a summary of the design chosen, design and scenario operating
characteristics, and a plot of the main operating characteristics shown in the browser window.
This allows a record of evaluated designs to be stored, presented and subsequently compared to
operating characteristics from other dose-escalation designs if required.
AplusB: AWeb Application for Phase I Trials
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Results
We now examine four examples of dose-toxicity scenarios, each of which will be evaluated by a
particular A + B design. We use a 3 + 3 design with dose de-escalation not permitted to evaluate
examples I and II, and a 3 + 3 design with dose de-escalation permitted to evaluate example III.
For example IV, we use a 2 + 4 design with dose de-escalation permitted.
Fig 5. Example trial pathways for various A + B designs.
doi:10.1371/journal.pone.0159026.g005
AplusB: AWeb Application for Phase I Trials
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Example I shows a traditional 3 + 3 design applied to four dose levels with true DLT proba-
bilities equal to {0.05, 0.10, 0.33, 0.60} (Fig 6). The dose chosen as the MTD has either zero
DLTs out of three patients observed, or one DLT out of six patients. Using these data, the 95%
Clopper-Pearson confidence intervals for the estimated probability of DLT at the MTD are
(0%, 70.76%) and (0.42%, 64.12%) respectively. Dose level 2 has a 50% chance of being chosen
as the MTD, despite having a true DLT probability of 10%. Furthermore, there is a 3% chance
that no dose is selected as the MTD due to safety reasons, despite the lowest dose only having a
5% chance of causing a DLT. There is a 10% chance that patients will receive the highest dose,
which has a 60% chance of causing a DLT. On average 22% of patients will experience a DLT
(EOTR) and the ETL is 19%, much lower than the 33% that is often assumed in phase I trials
using the 3 + 3 design.
Example II shows a traditional 3 + 3 design applied to six dose levels with true probability of
DLT equal to {0.04, 0.08, 0.16, 0.32, 0.64, 0.80} (Fig 7). In this scenario, the chances of selecting
dose levels 3 and 4 as the MTD, which have true probabilities of DLT equal to 16% and 32%,
are 40% and 31% respectively. Although three dose levels have DLT probabilities of at most
Fig 6. Scenario plots for Example I.
doi:10.1371/journal.pone.0159026.g006
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16%, there is a 2% chance that no MTD will be found for safety reasons. Furthermore, there is
only a 19% chance that dose level 4 will be given to patients, with a 7% chance that dose level 5,
with true DLT probability of 64%, will be given to patients. Approximately 19% of patients will
experience DLT and the ETL under this scenario is 20%. For both examples I and II, the
design’s tipping point is 0.297, i.e. the dose most likely to be chosen as the MTD will have a
true DLT probability less than 0.297.
In example III, six doses were investigated in a 3 + 3 design with dose de-escalation permit-
ted, with true DLT probabilities {0.06, 0.15, 0.29, 0.31, 0.33, 0.35} (Fig 8). For this scenario, the
DLT probabilities plateau around the suspected target toxicity level of 33% (dose level 5).
Under this design, if an excessive number of DLTs are observed at the current dose level (at
least two DLTs out of three or six patients) and only three patients have received the dose level
immediately below, then the next three patients will be given the dose level immediately below.
With respect to MTD recommendation, there is only a 4% chance that dose level 5 is chosen as
the MTD at the end of the trial, and dose level 2 is the most likely dose to be chosen as the
MTD (39%). The 95% Clopper-Pearson confidence intervals for the estimated probability of
Fig 7. Scenario plots for Example II.
doi:10.1371/journal.pone.0159026.g007
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DLT at the MTD, at which we will have seen either zero or one DLT out of six patients, are
(0%, 45.93%) and (0.42%, 64.12%) respectively. Similar to example I, the ETL is 19% and the
EOTR is 20%. For experimentation, there is only a 4% chance that patients will be given dose
level 5, and a 62% that patients will receive dose levels 1 or 2. Since the dose-toxicity curve
becomes flat for the last four doses, the 3 + 3 design used here is unable to identify dose level 5
(or dose level 4, with true DLT probability of 0.31) with a suitable level of certainty, and most
patients will only receive the two lowest dose levels and not higher levels that are still consid-
ered tolerable.
Example IV evaluates a 2 + 4 design with {A, B, C, D, E} = {2, 4, 1, 1, 2} and permits dose de-
escalation before stopping the trial; this design is applied to five dose levels with true DLT
probabilities equal to {0.06, 0.20, 0.30, 0.40, 0.45} (Fig 9). Under this design, if no patients in
the two-patient cohort have DLTs, the dose is escalated. If one patient out of two has a DLT,
then four more patients are given the current dose, and if both patients in the two-person
cohort have a DLT, the dose is de-escalated to the previous level. When four extra patients are
given a particular dose, if two or fewer patients out of six experience DLT, then the dose is
Fig 8. Scenario plots for Example IV.
doi:10.1371/journal.pone.0159026.g008
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escalated, otherwise the dose is de-escalated. The 95% Clopper-Pearson confidence intervals
for the probability of DLT at the dose chosen as the MTD are (0%, 45.93%) (no DLTs out of six
patients), (0.42%, 64.12%) (one DLT out of six patients) and (4.33%, 77.72%) (two DLTs out of
six patients). There is a 29% chance that dose level 3 is recommended as the MTD, and a 26%
chance that patients in the trial will receive this dose level. If we assume that a 33% DLT proba-
bility is to be targeted, then the closest dose is dose level 3, yet there is a 38% chance that dose
levels 4 or 5 will be recommended as the MTD. Although the toxicity constraints are more
relaxed in this scenario than the previous two, there is approximately a 1% chance that no
MTD will be recommended. For this design, the tipping point is 0.448; here the modal MTD is
dose level 3, but there may exist other dose-toxicity scenarios where the modal MTD is actually
above the tipping point for this design.
Fig 9. Scenario plots for Example IV.
doi:10.1371/journal.pone.0159026.g009
AplusB: AWeb Application for Phase I Trials
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Comparison to pmtd program
The pmtd program, published by Lin and Shih [6], is another available tool that computes
operating characteristics for A + B designs. On a practical basis, the AplusB application is far
more useful than the pmtd program, since the AplusB application does not require software to
be downloaded and it is not necessary for the user to have any special programming experi-
ence. By comparison, the pmtd program requires the user to download either of the statistical
programs R or S-Plus, and also to be familiar with how to install packages and run code in each
program.
The AplusB application also provides a far more comprehensive analysis of A + B trial
designs than the pmtd program. The output of the pmtd program does not include plots of
operating characteristics, and only provides a mean number for some operating characteristics,
such as sample size and DLT rate. The AplusB application illustrates both the full distribution
of the trial sample size and the DLT rate, so clinicians can obtain a thorough understanding of
how large their trial is likely to be and what proportion of patients can be expected to experi-
ence DLT, even in unlikely scenarios. The AplusB application also provides confidence inter-
vals for the probability of DLT at doses that are chosen as the MTD and the tipping point of a
design; both of these are related to the trial design rather than a specific dose-toxicity scenario,
and so can inform clinicians if using an A + B design is really the best course of action for their
phase I trial. Furthermore, the results provided by AplusB can be quickly downloaded as a pre-
formatted PDF report so results can easily be presented to other investigators.
With regards to the calculations made by AplusB and pmtd, the main difference lies in how
the percentage of patients receiving each dose level are calculated. For the pmtd program, the
percentage is computed by dividing the average number of patients at a dose by the average
number of patients in a trial. The AplusB application, however, computes the percentage of
patients receiving a particular dose using the probability that each possible trial could occur,
therefore giving an exact answer, rather than an approximation. For all four examples, we com-
pared experimentation percentages from AplusB, which uses the probability of each trial path-
way occurring in its calculations, to those from the pmtd program [6] (Table 1). We found that
pmtd overestimates experimentation percentages at higher dose levels by up to 2.1% and under-
estimates experimentation at lower dose levels by up to 2.4%; this is because pmtd incorrectly
gives more weighting to trial pathways that escalate all the way to the maximum planned dose.
Computation times
We calculated mean computation times for generating all trial pathways for A + B designs with
A = B 2 {1, . . ., 6}, with between two and 10 dose levels using AplusB; we ran 100 independent
Table 1. Comparison of experimentation percentages for AplusB and pmtd for Examples I, II, III and IV.
Scenario Method Dose Level
1 2 3 4 5 6
I AplusB 29.8 30.3 29.9 10.0 - -
pmtd 27.6 29.4 31.0 12.0 - -
II AplusB 24.3 24.9 24.5 19.2 6.7 0.3
pmtd 22.1 23.6 24.6 21.0 8.3 0.4
III AplusB 29.8 32.0 22.9 9.8 4.0 1.4
pmtd 25.1 30.0 24.3 12.5 5.9 2.3
IV AplusB 20.4 26.7 25.8 18.3 8.8 -
pmtd 18.0 25.1 26.2 20.4 10.3 -
doi:10.1371/journal.pone.0159026.t001
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runs of each trial design using an AMD Opteron™ Processor 6174 2.2GHz running Linux
Ubuntu 12.04.5 LTS. For a 6 + 6 trial with {C, D, E} = {1, 1, 1} and 10 dose levels, the mean
computation time was 11.352 seconds (standard deviation 2.934 seconds). In general, compu-
tation time increases when C, D and E are not all equal and when de-escalation is permitted
(see S1, S2, S3 and S4 Tables).
Discussion
One of the main barriers to increasing the use of new and potentially superior dose-escalation
designs in phase I cancer trials has been a lack of user-friendly software [19, 20]. Whilst this is
often mentioned in reference to software for new designs that employ statistical models, it is
also important that user-friendly software is available for clinicians and investigators to better
understand methods that are firmly established in practice. Several papers have shown that
because A + B designs do not target an explicit probability of DLT for the MTD to have, the
true probability of DLT at a dose chosen to be the MTD is likely to vary greatly [9, 10]. Further-
more, since the MTD is often chosen based solely on the few patients that have received a par-
ticular dose, the uncertainty around the estimated probability of DLT at the MTD will be very
large [21]; Chiuzan et al. [22] showed that by analysing A + B designs under a classical statisti-
cal framework, there is often too little evidence to select the correct dose as the MTD based on
the numbers of patients treated per dose. Many comparative simulation studies have concluded
that other rule-based designs and also model-based designs are more likely to recommend cor-
rect doses as the MTD than the 3 + 3 design, as well as dose more trial patients at or around the
MTD [15, 23–29]. It is important that these aspects of a dose-escalation design are familiar to
the investigators, as some designs may be inherently more likely to recommend ineffective
doses for phase II testing, and thus increase the chance that a truly superior cancer treatment is
shelved due to lack of benefit.
For A + B designs, particularly the 3 + 3 design, several computer programs have been devel-
oped over the last 20 years to summarise how patients are likely to be treated and which doses
are likely to be recommended for further testing. However, all of these programs require spe-
cific knowledge of advanced statistical software. Also, these programs either provide a very lim-
ited set of operating characteristics for a design, or have been lost since publication.
We have created the AplusB application using the R package Shiny [14] to provide an up-
to-date tool for summarising A + B dose-escalation designs for phase I cancer trials. The
AplusB application has a graphical user interface and does not rely on the user having knowl-
edge of specialist statistical software. Comprehensive operating characteristics are provided,
both in tabular and graphical form, and can easily be downloaded as a pre-formatted report.
We have released this application on the internet for free (available at http://www.mrc-bsu.
cam.ac.uk/software), so that it is easily accessible and more likely to be useful to clinical
researchers working in drug development. In addition to this, the code for the AplusB appli-
cation may also be downloaded from GitHub (https://github.com/graham-wheeler/AplusB)
and run remotely on the user’s machine without an internet connection (the R program is
required and easy-to-follow setup instructions are provided).
We have demonstrated and discussed how the AplusB application is superior to it’s next-
best competitor, the S-Plus program pmtd [6], with respect to accessibility, ease of use, accu-
racy of computation and comprehensiveness of operating characteristics produced. We envis-
age that this tool will be useful to investigators and clinicians working in phase I cancer trials,
both for understanding the implications of using A + B designs and for comparing the operat-
ing characteristics of A + B designs to other dose-escalation designs, and welcome feedback
and comments on its performance.
AplusB: AWeb Application for Phase I Trials
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Supporting Information
S1 Text. Operating characteristics and formulae. A list of operating characteristics provided
by the AplusB app and their formulae.
(PDF)
S2 Text. Relationship between tipping point and MTD selection. Two theorems with proofs
on the relationship between the tipping point and the probability of selecting a dose as the
MTD.
(PDF)
S1 Table. Mean computation times in seconds for A + B designs. Assumed A = B, {C, D, E} =
{1, 1, 1} and de-escalation is not permitted. n = 100.
(PDF)
S2 Table. Standard deviation of computation times in seconds for A + B designs. Assumed
A = B, {C, D, E} = {1, 1, 1} and de-escalation is not permitted. n = 100.
(PDF)
S3 Table. Mean computation times in seconds for A + B designs. Assumed A = B, {C, D, E} =
{1, 1, 2} and de-escalation is not permitted. n = 100.
(PDF)
S4 Table. Standard deviation of computation times in seconds for A + B designs. Assumed
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